Newborn gene screening study in France
Part of Genetic & congenital clinical trials.
This study is testing a new way to screen newborns for certain health conditions by analyzing their DNA from a small blood sample. It aims to see if parents find this type of screening acceptable and helpful.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Your baby is born in one of the participating maternity centers or your baby's care will be provided there.
- Your baby is less than 28 days old when the blood sample is taken.
- At least one biological parent has received information about the study and can give permission for the baby to be tested.
- You are not under legal guardianship or a court order.
- Your baby is not born under anonymous birth (French law 'nés sous X').
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This pilot study tries a systematic way to look for several rare “lysosomal storage” diseases in newborns using a specialized lab test on routine blood samples. It may help detect these conditions earlier so treatment can start sooner if needed.
This study is for children or adults with neurodevelopmental conditions and unusual physical features, where standard genetic tests haven't found a cause. Researchers will use RNA and DNA sequencing to look for hidden genetic explanations, which could guide better care.
This study tries to find genetic causes for rare diseases that are not yet understood. It uses a national rare-disease data bank and collects consent from patients and sometimes close family members.
This research study tests a new way to screen newborns for hundreds of genetic diseases using a sample of their blood or saliva. It aims to find conditions early so your baby can get the right care sooner.
This study tests a new way to screen newborns for rare genetic diseases using a blood sample. It aims to find treatable conditions early so that babies can get care sooner.
This study talks to parents whose newborns had a screening test for spinal muscular atrophy (SMA) in two French regions. The goal is to understand how parents experienced that screening process—good or bad—so hospitals can improve how they share results.
Hear when a new Newborn Screening Programmes for Rare Diseases trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.